Galderma sues Lupin over Oracea generic
Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea prior to the expiration of key patents.
J&J secures injunction against medical device counterfeiter
Johnson & Johnson’s subsidiary Ethicon has obtained a permanent injunction against counterfeiters selling fake versions of Surgicel, an absorbable haemostat used to control bleeding during surgery.
BGI hit with $8m damages bill in patent dispute with Illumina
Illumina has secured an $8 million damages verdict against China-based BGI Genomics, and its US subsidiary, MGI, in a dispute involving gene-sequencing patents.
Moderna exposed after losing COVID-19 vaccine patent decision
Moderna has failed to reverse an unfavourable ruling related to its COVID-19 vaccine technology, after the US Court of Appeals for the Federal Circuit upheld the validity of a patent owned by Arbutus Biopharma.
Fed Circuit split decision denies Biogen’s bid to revive MS drug patent
The US Court of Appeals for the Federal Circuit has refused Biogen’s attempt to revive a key patent for its multiple sclerosis drug Tecfidera (dimethyl fumarate), leaving Mylan’s successful challenge intact.
Biofrontera settles patent dispute with Dusa over skin treatment
A US subsidiary of German skin treatment company Biofrontera has resolved its dispute with Dusa Pharmaceuticals, on the eve of a trial over patents covering a light therapy used to treat skin conditions, called BLU-U.
Fed Circ says Indivior patent was anticipated
The US Court of Appeals for the Federal Circuit has affirmed a US Patent Trial and Appeal Board decision that held that claims of a patent for dissolvable films containing therapeutic agents were anticipated.
Omicron variant delays COVID-19 IP waiver debate
The World Trade Organization has postponed its ministerial conference indefinitely, potentially ending the opportunity for countries to agree an IP waiver for COVID-19 vaccines this year.
Court denies Sun Pharma’s bid to avoid trial
Sun Pharma’s bid to avoid facing a trial over allegations of antitrust behaviour by an Indian drugmaker it acquired has been denied by a Massachusetts court.
Fed Circ invaded jury’s role in Repatha case, says Amgen
Amgen has urged the US Supreme Court to wade into its legal wrangle with Sanofi and Regeneron Pharmaceuticals over patents covering a cholesterol drug, Repatha.
